Literature DB >> 33369035

Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.

R S Ying1, T Le2,3, W P Cai1, Y R Li4, C B Luo1, Y Cao1, C Y Wen1, S G Wang1, X Ou1, W S Chen1, S Z Chen1, P L Guo1, M Chen5, Y Guo4, X P Tang1, L H Li1.   

Abstract

OBJECTIVES: Talaromycosis is an invasive mycosis endemic to Southeast Asia. This study aimed to investigate the epidemiology, clinical features and prognostic factors of HIV-associated talaromycosis in Guangdong, China.
METHODS: We retrospectively evaluated HIV patients hospitalized with histopathology- or culture-confirmed talaromycosis between 2011 and 2017. Factors associated with poor prognosis were identified using logistic regression.
RESULTS: Overall, 1079 patients with HIV-associated talaromycosis were evaluated. Both the number and prevalence of talaromycosis among HIV admissions increased from 125 and 15.7% in 2011 to 253 and 18.8% in 2017, respectively, reflecting the increase in HIV admissions. Annual admissions peaked during the rainy season between March and August. Common clinical manifestations included fever (85.6%), peripheral lymphadenopathy (72.3%), respiratory symptoms (60.8%), weight loss (49.8%), skin lesions (44.5%) and gastrointestinal symptoms (44.3%). Common laboratory abnormalities were hypoalbuminaemia (98.6%), anaemia (95.6%), elevated aspartate aminotransferase level (AST) (76.9%), elevated alkaline phosphatase level (55.8%) and thrombocytopenia (53.7%). The median CD4 count was 9 cells/μL. Talaromyces marneffei was isolated from blood and bone marrow cultures of 66.6% and 74.5% of patients, respectively. The rate increased to 86.6% when both cultures were performed concurrently. At discharge, 14% of patients showed worsening conditions or died. Leucocytosis, thrombocytopenia, elevated AST, total bilirubin, creatinine and azole monotherapy independently predicted poor prognosis.
CONCLUSIONS: The incidence of HIV-associated talaromycosis has increased in Guangdong with the high HIV burden in China. Skin lesions were seen in less than half of patients. Induction therapy with azole alone is associated with higher mortality. Findings from this study should help to improve treatment of the disease.
© 2020 British HIV Association.

Entities:  

Keywords:  China; HIV; Talaromyces marneffei; penicilliosis; talaromycosis

Year:  2020        PMID: 33369035      PMCID: PMC7978497          DOI: 10.1111/hiv.13024

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  28 in total

1.  Clinical Characteristics and Prognosis of Penicilliosis Among Human Immunodeficiency Virus-Infected Patients in Eastern China.

Authors:  Jun Chen; Renfang Zhang; Yinzhong Shen; Li Liu; Tangkai Qi; Zhenyan Wang; Wei Song; Yang Tang; Hongzhou Lu
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

2.  Isolation of Talaromyces marneffei from the Skin of an Egyptian Mongoose ( Herpestes ichneumon) in Portugal.

Authors:  Ana C Matos; Daniela Alves; Sofia Saraiva; Ana S Soares; Tatiana Soriano; Luis Figueira; Fátima Fraga; Manuela Matos; Ana C Coelho
Journal:  J Wildl Dis       Date:  2018-06-28       Impact factor: 1.535

3.  Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.

Authors:  Thuy Le; Marcel Wolbers; Nguyen Huu Chi; Vo Minh Quang; Nguyen Tran Chinh; Nguyen Phu Huong Lan; Pham Si Lam; Michael J Kozal; Cecilia M Shikuma; Jeremy N Day; Jeremy Farrar
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

4.  Serological surveillance for Penicillium marneffei infection in HIV-infected patients during 2004-2011 in Guangzhou, China.

Authors:  Y-F Wang; H-F Xu; Z-G Han; L Zeng; C-Y Liang; X-J Chen; Y-J Chen; J-P Cai; W Hao; J F-W Chan; M Wang; N Fu; X-Y Che
Journal:  Clin Microbiol Infect       Date:  2014-12-26       Impact factor: 8.067

5.  Rapid and robust identification of clinical isolates of Talaromyces marneffei based on MALDI-TOF mass spectrometry or dimorphism in Galleria mellonella.

Authors:  Andrew M Borman; Mark Fraser; Adrien Szekely; Elizabeth M Johnson
Journal:  Med Mycol       Date:  2019-11-01       Impact factor: 4.076

6.  Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir?

Authors:  S Chariyalertsak; T Sirisanthana; K Supparatpinyo; K E Nelson
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

7.  Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus.

Authors:  Yu-Tsung Huang; Chien-Ching Hung; Chun-Hsing Liao; Hsin-Yun Sun; Shan-Chwen Chang; Yee-Chun Chen
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

8.  Penicillium marneffei infection: an emerging disease in mainland China.

Authors:  Yongxuan Hu; Junmin Zhang; Xiqing Li; Yabo Yang; Yong Zhang; Jianchi Ma; Liyan Xi
Journal:  Mycopathologia       Date:  2012-09-17       Impact factor: 2.574

9.  Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study.

Authors:  J Jiang; S Meng; S Huang; Y Ruan; X Lu; J Z Li; N Wu; J Huang; Z Xie; B Liang; J Deng; B Zhou; X Chen; C Ning; Y Liao; W Wei; J Lai; L Ye; F Wu; H Liang
Journal:  Clin Microbiol Infect       Date:  2018-04-24       Impact factor: 8.067

10.  Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis.

Authors:  Nguyen T M Thu; Jasper F W Chan; Vo Trieu Ly; Hoa T Ngo; Ha T A Hien; Nguyen P H Lan; Nguyen V V Chau; Jian-Piao Cai; Patrick C Y Woo; Jeremy N Day; Rogier van Doorn; Guy Thwaites; John Perfect; K Y Yuen; Thuy Le
Journal:  Clin Infect Dis       Date:  2020-06-21       Impact factor: 9.079

View more
  7 in total

Review 1.  Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.

Authors:  Xiaochun Xue; Jun Zou; Wenjie Fang; Xiaogang Liu; Min Chen; Amir Arastehfar; Macit Ilkit; Yanqing Zheng; Jianglong Qin; Zhipeng Peng; Dongying Hu; Wanqing Liao; Weihua Pan
Journal:  Mycopathologia       Date:  2022-02-14       Impact factor: 2.574

2.  Talaromyces marneffei infection associated with bronchiolitis obliterans in an HIV-negative child: a case report.

Authors:  Lin Lin; Huifeng Fan; Dongwei Zhang; Gen Lu
Journal:  BMC Infect Dis       Date:  2022-05-16       Impact factor: 3.667

Review 3.  Future Directions for Clinical Respiratory Fungal Research.

Authors:  Darius Armstrong-James
Journal:  Mycopathologia       Date:  2021-09-29       Impact factor: 2.574

4.  Talaromyces marneffei Mp1p Antigen Detection may Play an Important Role in the Early Diagnosis of Talaromycosis in Patients with Acquired Immunodeficiency Syndrome.

Authors:  Xiaoman Chen; Xu Ou; Haodi Wang; Liya Li; Pengle Guo; Xiejie Chen; Weiping Cai; Xiaoping Tang; Linghua Li
Journal:  Mycopathologia       Date:  2022-03-03       Impact factor: 3.785

5.  Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China.

Authors:  Minjuan Shi; Jianyan Lin; Wudi Wei; Yaqin Qin; Sirun Meng; Xiaoyu Chen; Yueqi Li; Rongfeng Chen; Zongxiang Yuan; Yingmei Qin; Jiegang Huang; Bingyu Liang; Yanyan Liao; Li Ye; Hao Liang; Zhiman Xie; Junjun Jiang
Journal:  PLoS Negl Trop Dis       Date:  2022-05-04

6.  Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.

Authors:  Yihong Zhou; Yuanyuan Qin; Yanqiu Lu; Jing Yuan; Jingmin Nie; Min Liu; Qun Tian; Ke Lan; Guoqiang Zhou; Yingmei Qin; Kaiyin He; Jianhua Yu; Zhongsheng Jiang; Jun Liu; Shuiqing Liu; Vijay Harypursat; Yaokai Chen
Journal:  Infect Dis Ther       Date:  2022-06-11

7.  Gastrointestinal Talaromyces marneffei infection in a patient with AIDS: A case report and systematic review.

Authors:  Fangmei Ling; Tao Guo; Junrong Li; Yidong Chen; Mingyang Xu; Shuang Li; Liangru Zhu
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.